 |
|
|
| |
Regression of Fibrosis/Cirrhosis with Long-Term Entecavir Therapy in Chronic Hepatitis B (CHB) Patients with Baseline Bridging Fibrosis or Cirrhosis: Results from Studies ETV-022, -027 and -901
|
| |
| |
DDW Chicago May 30-June 4 2009
Reported by Jules Levin
Eugene R Schiff1, Samuel S Lee2,You-Chen Chao3, SeungKew Yoon4, Fernando Bessone5, Shun-Sheng Wu6, Wieslaw Kryczka7, Yoav Lurie8, Adrian Gadano9, George Kitis10, Suzanne Beebe11, Bruce Kreter12, Dong Xu11, Melissa Harris13, Hong Tang13, Uchenna Iloeje11
1University of Miami Hospital & Clinics, Miami, FL, USA; 2Liver Unit, University of Calgary, Calgary, AB, Canada; 3Tri-Service General Hospital, Taipei, Taiwan; 4Department of Internal Medicine, Kangnam St Mary's Hospital, Seoul, Korea; 5Rosario, Santa Fe, Argentina; 6Department of Internal Medicine, Changhua Christian Hospital, Changhua,Taiwan; 7Wojewodzki Szpital Zespolony, Kielce, Poland; 8Department of Gastroenterology, Tel Aviv Medical Center, Tel Aviv, Israel; 9Hospital Italiano Regional Del Sur, Buenos Aires, Argentina; 10George Papanikolaou Hospital, Gastroenterology Department, Thessaloniki, Greece; 11Research & Development, Bristol-Myers Squibb Company, Wallingford, CT, USA; 12Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA; 13Research & Development, Bristol-Myers Squibb Company, Plainsboro, NJ, USA
|
| |
|
|
|
|
|
